NCT04326920View on ClinicalTrials.gov

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

February 26, 2021

Conditions
COVID-19
Interventions
DRUG

Sargramostim

Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration

OTHER

Control

Standard of care

Trial Locations (4)

1090

UZ Brussel, Jette

8000

AZ Sint Jan Brugge, Bruges

8800

AZ Delta Roeselare, Roeselare

9000

University Hospital Ghent, Ghent

All Listed Sponsors
collaborator

Flemish institute of biotechnology (VIB)

OTHER

lead

University Hospital, Ghent

OTHER

NCT04326920 - Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) | Biotech Hunter | Biotech Hunter